XtalPi is a cloud-based technology company that solves drug polymorphism by providing accurate computational crystal structure prediction for small-molecule drugs. As an industry pioneer, XtalPi applies its expertise in drug virtual development to create game-changing solutions for polymorph screening with unbeatable speed and accuracy. With a mission to make safe and effective treatments available to patients worldwide faster, XtalPi is dedicated to accelerate drug development for biopharmaceutical companies worldwide by translating leading-edge science and computational technology into R&D efficiency. Its technology holds the promise of revolutionizing the industry standard for drug development risk management, crystal form patent strategy, and lifecycle management. Founded in 2014 by a group of quantum physicists on MIT campus, XtalPi has since grown into an elite team of 30 people with diverse backgrounds. It has received much recognition for its groundbreaking technology, innovative solution, and its potential for wide application across the pharmaceutical industry.